Research & Development

Recursion secures NIH phase 2 SBIR grant to discover senolytic drug candidates

Recursion Pharmaceuticals, which combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs, has been given a $1.6m Phase 2 Small Business Innovation Research (SBIR) award from the National Institutes of Health (NIH) through the National Institute on Aging (NIA).

BioTime signs merger deal with Asterias Biotherapeutics

Clinical-stage biotechnology firm BioTime has signed an agreement to acquire the remaining stake in Asterias Biotherapeutics for an undisclosed sum.

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

US-based Brooklyn ImmunoTherapeutics, a newly formed company, has acquired the assets of IRX Therapeutics for an undisclosed price.

Shire agrees to license rare liver disease candidates to Mirum

Shire has agreed to license exclusive worldwide rights to two rare cholestatic liver disease candidates, including the maralixibat oral inhibitor, to clinical-stage therapeutics company Mirum Pharmaceuticals.

Alexion wraps up $1.2bn acquisition of Syntimmune

Alexion Pharmaceuticals has wrapped up its previously announced acquisition of US-based clinical-stage biotechnology firm Syntimmune in a deal worth $1.2bn.

Gilead, Tango to partner on targeted immuno-oncology therapies

Gilead Sciences and Tango Therapeutics have entered into a global collaboration to discover, develop and commercialize a pipeline of targeted immuno-oncology treatments for cancer.

Terns raises $80m to advance drug pipeline for NASH and cancer treatment

Terns Pharmaceuticals, a biopharma company focused on discovering and developing molecularly targeted, oral, small-molecule drugs for the treatment of NASH and cancer, has raised $80m through a Series B financing round.

Lilly, Dicerna to collaborate on RNAi research for several targets

Eli Lilly and Company (Lilly) and Dicerna Pharmaceuticals have signed a global licensing and research collaboration focused on the discovery, development and commercialization of new drugs in the areas of cardio-metabolic disease, neurodegeneration and pain.

Alexion, Dicerna to discover RNAi Therapies for complement-mediated diseases

Alexion Pharmaceuticals and Dicerna Pharmaceuticals have entered into a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases.